JNJ

228.79

+1.07%↑

ABT

91.63

-1.56%↓

MDT

83.72

+0.78%↑

A

114.82

-5.85%↓

VEEV

154.43

-6.56%↓

JNJ

228.79

+1.07%↑

ABT

91.63

-1.56%↓

MDT

83.72

+0.78%↑

A

114.82

-5.85%↓

VEEV

154.43

-6.56%↓

JNJ

228.79

+1.07%↑

ABT

91.63

-1.56%↓

MDT

83.72

+0.78%↑

A

114.82

-5.85%↓

VEEV

154.43

-6.56%↓

JNJ

228.79

+1.07%↑

ABT

91.63

-1.56%↓

MDT

83.72

+0.78%↑

A

114.82

-5.85%↓

VEEV

154.43

-6.56%↓

JNJ

228.79

+1.07%↑

ABT

91.63

-1.56%↓

MDT

83.72

+0.78%↑

A

114.82

-5.85%↓

VEEV

154.43

-6.56%↓

Search

CareDx Inc

Cerrado

SectorSanidad

20 -3.66

Resumen

Variación precio

24h

Actual

Mínimo

20.49

Máximo

21.05

Métricas clave

By Trading Economics

Ingresos

-5.8M

-4.1M

Ventas

8.3M

108M

P/B

Media del Sector

14.645

60.328

BPA

0.12

Margen de beneficios

-3.79

Empleados

761

EBITDA

-5.7M

1.5M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+20.6% upside

Dividendos

By Dow Jones

Próximas Ganancias

28 abr 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

95M

1.1B

Apertura anterior

23.66

Cierre anterior

20

Noticias sobre sentimiento de mercado

By Acuity

29%

71%

114 / 348 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

CareDx Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

23 abr 2026, 00:00 UTC

Noticias de Eventos Importantes

Australian Flash PMI Bounce in April Conceals Deeper Worries

22 abr 2026, 23:33 UTC

Ganancias

SK Hynix Posts Record Quarterly Results Amid AI Boom

22 abr 2026, 22:40 UTC

Ganancias

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22 abr 2026, 22:10 UTC

Adquisiciones, fusiones, absorciones

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22 abr 2026, 21:11 UTC

Ganancias

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22 abr 2026, 21:01 UTC

Ganancias

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22 abr 2026, 23:46 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

22 abr 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22 abr 2026, 23:34 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22 abr 2026, 23:16 UTC

Ganancias

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22 abr 2026, 23:15 UTC

Ganancias

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22 abr 2026, 22:54 UTC

Ganancias

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22 abr 2026, 22:54 UTC

Ganancias

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22 abr 2026, 22:52 UTC

Ganancias

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22 abr 2026, 22:51 UTC

Ganancias

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22 abr 2026, 22:31 UTC

Ganancias

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22 abr 2026, 22:31 UTC

Ganancias

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22 abr 2026, 22:30 UTC

Ganancias

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22 abr 2026, 22:30 UTC

Ganancias

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22 abr 2026, 22:29 UTC

Ganancias

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22 abr 2026, 22:28 UTC

Ganancias

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22 abr 2026, 22:28 UTC

Ganancias

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22 abr 2026, 22:27 UTC

Ganancias

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22 abr 2026, 22:06 UTC

Charlas de Mercado
Ganancias

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22 abr 2026, 21:55 UTC

Adquisiciones, fusiones, absorciones

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22 abr 2026, 21:47 UTC

Ganancias

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 abr 2026, 21:37 UTC

Ganancias

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22 abr 2026, 21:34 UTC

Ganancias

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22 abr 2026, 21:29 UTC

Ganancias

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 abr 2026, 21:20 UTC

Charlas de Mercado
Ganancias

Tesla Expands Manufacturing to Chips -- Market Talk

Comparación entre iguales

Cambio de precio

CareDx Inc previsión

Precio Objetivo

By TipRanks

20.6% repunte

Estimación a 12 Meses

Media 25 USD  20.6%

Máximo 28 USD

Mínimo 21 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CareDx Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

2

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

14.77 / 18.49Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

114 / 348 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat